

Intensive Care Unit Management of Meningitis and Encephalitis



Destiny Marquez, MD, MA^a,
Neha Subhash Dangayach, MD, MSCR^{b,*}

KEYWORDS

- Meningitis • Encephalitis • Intracranial pressure management • Hydrocephalus
- Cryptococcus • Rhombencephalitis

KEY POINTS

- Meningitis and encephalitis are uncommonly encountered infections that are associated with significant morbidity and mortality.
- Though the classic triad of fever, meningismus, and headache may be present, clinical features may vary by pathogen and may be associated with unique risk factors that could facilitate empirical antimicrobial administration.
- In addition to antibiotics, steroids, and anti-seizure medications, management of elevated intracranial pressure (ICP) and hydrocephalus may necessitate a stepwise approach that could culminate in the need for decompressive surgical craniotomy.
- In patients with elevated ICP, cerebrospinal fluid diversion via intracranial devices, lumbar drains, or serial lumbar punctures has demonstrated improved clinical outcomes and decreased morbidity.

INTRODUCTION

Meningitis and encephalitis are uncommon causes of infections that can lead to critical illness and represent 2.9% of all cases in the ICU.¹ Meningitis is an inflammation of the membranes that surround the brain and spinal cord, called the meninges, while encephalitis is an inflammation of the brain itself. Despite the low prevalence, CNS infections cause high rates of long-term neurological sequelae and mortality. Mortality rates for bacterial meningitis vary from 10% in high-income countries to 58% in low-income countries with up to 25% with residual focal neurologic deficits.²

^a Neurocritical Care Division, Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA; ^b Neurocritical Care Division, Departments of Neurosurgery, Neurology, Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai, New York, NY, USA

* Corresponding author. 1 Gustave L. Levy Place, Annernberg 8-42B, New York, NY 10029.

E-mail address: neha.dangayach@mountsinai.org

Abbreviations	
ABC	airway, breathing, and circulatory support
ASM	anti-seizure medication
CMV	cytomegalovirus
CSF	cerebrospinal fluid
CT	computed tomography
EEG	electroencephalography
FLAIR	fluid-attenuated inversion recovery
GCS	Glasgow Coma Scale
HIV	Human Immunodeficiency Virus
HOB	head of bed
HSV	Herpes Simplex virus
ID	Infectious Diseases
IDSA	Infectious Diseases Society of America
LD	lumbar drains
LP	lumbar puncture
MRI	magnetic resonance imaging
NCS	Neurocritical Care Society
TB	tuberculosis
TBM	tuberculous meningitis
VZV	Varicella Zoster virus

Encephalitis mortality rates are similarly elevated at 5.6% to 39.3% with survivors suffering profound neurologic deficits like memory, attention, and vision impairments.³ When treating meningitis and encephalitis, prompt recognition, identification of the pathogen and management are crucial in decreasing the risk of neurologic injury and death. In this article, we will review clinical presentations and evidence-based management strategies for meningitis and encephalitis.

CLINICAL PRESENTATIONS AND RISK FACTORS

The hallmark features of meningitis and encephalitis include altered mental status, fever, headache, and meningismus. In bacterial meningitis, these symptoms may present in isolation or in combination with one another. Several studies have reported at least two of these symptoms being present in at least 72% to 95% of patients, with only 44% having the classic triad of fever, headache, and meningismus.^{4,5} Seizures as a presenting symptom is more common in encephalitis.^{5,6} Other non-specific symptoms may be lethargy, photophobia, nausea, vomiting, and rash. In some cases, unique clinical features alongside close identification of risk factors may aid in diagnosis and management.

Table 1 highlights pathogen-specific risk factors and unique clinical features.

The most common causes of bacterial meningitis include *Neisseria meningitidis*, *Streptococcus pneumoniae*, *Haemophilus influenza* type b, Group B *Streptococcus* (GBS), *Escherichia coli*, *Salmonella* sp., *Klebsiella*, sp. *Staphylococcus aureus*, *Listeria monocytogenes*, and *Mycobacterium tuberculosis*.⁷ On the other hand, viruses—including Herpes Simplex virus (HSV), Varicella Zoster virus (VZV), enteroviruses, and arboviruses—are the most common cause of infectious encephalitis, ranging from 1.4 to 13.8 cases per 100,000 persons per year worldwide.^{8,9} Risk factors for viral encephalitides are poorly understood but extremes of age and an immunocompromised state have been frequently reported. HSV encephalitis may present with temporal lobe hemorrhages, focal changes on electroencephalography (EEG), and hyponatremia.^{9,10}

Severe manifestations of fungal infections include meningitis and one of the most common fungal etiologies being *Cryptococcus neoformans*.¹¹ Of one million cases

Table 1

Summary of risk factors and unique clinical features of common pathogens

Pathogen	Risk Factors	Clinical Features
<i>Neisseria meningitidis</i>	Complement pathway deficiencies, asplenia, chronic disease, large group gatherings, Human Immunodeficiency Virus infection, exposure to the African meningitis belt, and active or passive smoking ²¹	Petechial rash → larger purpuric rash (42%–70%) → necrosis/purpura fulminans (25%) ²² DIC, coma, adrenal hemorrhage, death ^{23,24}
<i>Streptococcus pneumoniae</i>	Immunocompromised states, HIV, splenectomy, DM, alcoholism ²⁵	Cerebrovascular complications—arterial stroke (30%), venous sinus thrombosis (9%), intracranial hemorrhage (9%) High risk of long-term neurological sequela, such as hearing loss (up to 50% of cases) ²⁶ Death even with appropriate clinical management (20%) ²⁷
<i>Listeria Monocytogenes</i>	Consumption of contaminated soft cheeses, processed meats, livestock, raw produce, foods with a long shelf-half life ²⁸ Chronic kidney or liver disease, pregnancy, age over 50 ²⁹	Rhombencephalitis Asymmetric cranial nerve palsies, cerebellar signs, hemiparesis, hemisensory loss ³⁰
<i>Mycobacterium Tuberculosis</i>	Young age (especially < 5), HIV, immunosuppression ^{15–17} Farmers, miliary TB, malnutrition ¹⁸	Three phases ¹⁹ : • Prodromal • Meningitic • Paralytic
Herpes simplex virus	Extremes of age, immunocompromise, HIV ⁹	Temporal lobe hemorrhages, hyponatremia, focal EEG changes ⁹
Varicella zoster virus	Older age, HIV, hematologic malignancies, glucocorticoids, chronic obstructive pulmonary disorder, DM, solid cancer, stroke, congestive heart failure ³¹	Confusion, nausea, headache, gait disturbance, personality changes ³²
<i>Cryptococcus neoformans</i>	Immunocompromised state, HIV, chronic steroid use, chronic kidney, liver, lung disease, malignancy, transplants, iatrogenic ^{11,33}	Subacute to chronic onset Headache, intracranial hypertension, altered mental status, photophobia, seizures ^{3,12}
<i>Coccidioides</i> spp.	Filipino and African American descent, DM, and third trimester pregnancies, less commonly immunocompromise ³³	Intracranial hypertension, altered sensorium, neuropsychiatric symptoms ³⁴

(continued on next page)

Table 1 (continued)		
Pathogen	Risk Factors	Clinical Features
<i>Candida</i> spp.	Infants Neurosurgical procedures, most commonly ventriculoperitoneal shunts, lumbar cistern peritoneal shunts, external ventricular drains, and ventriculostomies ^{35,36}	Neonates: systemic symptoms Post-surgical: meningeal signs and altered mental status ³⁷
<i>Histoplasma</i> spp.	Immunocompromise ³⁸	Subacute to chronic onset of meningeal symptoms
<i>Naegleria fowleri</i>	Exposure to warm freshwater, nasal irrigation with contaminated water ³⁹	Rapidly progressive meningitis, high mortality
<i>Balamuthia</i> spp. <i>Acanthamoeba</i> spp.	Immunocompromise, diabetes, pregnancy, and liver disease ⁴⁰	Subacute onset of meningeal symptoms ⁴⁰
<i>Toxoplasma gondii</i>	Malignancy, HIV, immunosuppressive agents, pregnancy, primary ingestion of undercooked meat ^{41,42}	Subacute onset of focal neurologic deficits, seizures, and altered mental status Signs and symptoms of elevated intracranial pressure ⁴³

Data from refs. ^{3,9,11,12,15–19,21–30}

of cryptococcus globally, the incidence of cryptococcus meningitis has been reported at 223,000.¹² Other less common causes of fungal meningitis include *Coccidioides* sp., *Candida* sp., and *Histoplasma capsulatum*.

Finally, extremely rare causes of meningitis and encephalitis include protozoan parasites and typically follow a subacute onset of meningeal symptoms. These organisms include *Naegleria fowleri*, *Acanthamoeba* sp., *Balamuthia* sp., and *Toxoplasma gondii* and are also included in **Table 1**.

Tuberculosis (TB) is one of the most prevalent diseases in the world, affecting 10 million people a year.^{13,14} Of these, 2% to 5% may develop tuberculous meningitis (TBM).¹⁵ Risk factors include young age, Human Immunodeficiency Virus (HIV) infection, a previous history of miliary TB, malnutrition, and other causes of immunosuppression.^{15–18} Though symptoms of TBM may be variable and non-specific, three phases have been described. The prodromal phase begins with the subacute onset of cough, fever, malaise, weight loss, and the gradual onset of headache. Within a few weeks, the meningitic phase emerges, with symptoms characterized by meningismus, headache, cranial nerve palsies, and confusion.¹⁹ Unfortunately, by this stage, a rapid deterioration into the third paralytic phase of TBM occurs, which is defined by coma, seizure, hemiplegia, and death.^{16,19} Atypical presentations may include progressive dementia and personality changes.^{16,20}

DIAGNOSTIC WORKUP

Diagnosing meningitis and encephalitis promptly is imperative for instituting targeted treatments. The first step is obtaining a detailed history for symptoms and identification of pathogen-specific risk factors. Additionally, key physical examination findings

include meningismus, focal neurologic deficits, papilledema, rashes, and altered sensorium. In cases with high clinical suspicion, empiric treatment for meningitis/encephalitis must be instituted with broad spectrum antimicrobials with or without steroids depending upon the clinical suspicion for bacterial, viral versus fungal or tuberculous meningitis.

Laboratory Workup

Serum and cerebrospinal fluid (CSF) testing, highlighted in [Table 2](#), should be sent promptly as part of the workup but should not delay initiation of empirical antibiotics. A lumbar puncture (LP), which is the gold standard for diagnosis, should also be pursued as soon as possible.⁴⁴ [Table 3](#) summarizes normal and abnormal CSF profiles by pathogen.^{45–53} These values are not absolute and may vary among patients, especially in partially treated infections. Of note, if done in the early acute phase of meningitis or encephalitis, an LP may yield negative results. If the suspicion remains high, it is important to repeat the LP. For HSV encephalitis, false negatives are not uncommon when an LP is performed within 72 hours of illness. In a retrospective multicenter study of critically ill patients admitted for possible encephalitis, 4% of patients tested negative within 4 days of symptom onset, leading to delayed treatment.⁵⁴ The Infectious Diseases Society of America (IDSA) therefore recommends re-testing CSF within 3 to 7 days and continuation of antibiotics during this time.⁵⁵ Additionally, broadening the workup is sometimes required to identify the causative agent. Of note, limitations do exist with multiplex PCR panels. Firstly, they include the most common pathogens for meningitis and encephalitis; and, individualized evaluation of a patient's risk factors should warrant a more expanded workup for pathogens not included in the multiplex panel. Secondly, in a meta-analysis, multiplex panels were found to have moderate sensitivities but excellent specificities for both bacteria and viruses.⁵⁶ As such, these panels are excellent for ruling in pathogens but are not as effective for ruling out pathogens. More specifically, for bacteria, the sensitivity and specificity were 89.5% and 97.4%, respectively. For viruses, the sensitivity and specificity were at least 75.5% and 99%, respectively.^{2,56} Moreover, for specific pathogens, such as *Listeria monocytogenes*, *Hemophilus influenzae*, and *Escherichia coli*, the validity of the multiplex PCR panel was suboptimal.⁵⁶ Additionally, in another meta-analysis of 113 studies by Tansarli and colleagues, HSV-1 and 2, enterovirus,

Table 2
Laboratory diagnosis of meningitis and encephalitis

Basic Serum Studies • Complete blood count with differential • Basic metabolic panel • Blood cultures • Erythrocyte sedimentation rate • C-reactive protein • HIV Expanded: • 1,3-Beta-D-glucan • Aspergillus Galactomannan antigen • Venereal Disease Research Laboratory	Basic CSF Studies: • Cell count and differential • Protein • Glucose • Culture and gram stain • Meningitis/Encephalitis panel Expanded • 1,3-Beta-D-glucan • Aspergillus Galactomannan antigen • Cryptococcus antigen and fungal culture • HSV, VZV, Cytomegalovirus PCR • West Nile Virus IgM and IgG antibody • Toxoplasma CSF PCR, IgM, and IgG
---	---

Data from Ref.³

Table 3
Cerebrospinal fluid profiles in meningitis and encephalitis

	Normal	Bacterial	Viral	Fungal	TB	Parasitic ^a
Color	Clear	Cloudy, purulent	Clear	Clear	Clear	Clear
Opening Pressure (cm H ₂ O)	6–25	Elevated	Normal	Variable	Variable	Variable
WBC Count (cells/ μ L) and Differential	0–5 Rare PMNs	Elevated (typically > 1000) PMN predominance	Normal to mildly elevated (typically < 150) Lymphocytic predominance	Elevated (typically 100–500) Lymphocytic predominance	Elevated (typically 100–500) Lymphocytic predominance	Elevated May have eosinophilia
Protein (mg/dL)	15–45	Elevated	Normal to mildly elevated	Elevated	Elevated	Elevated
Glucose (mg/dL)	45–80 60%–80% of serum glucose	Reduced	Normal	Significantly reduced	Significantly reduced	Low normal-normal

^a Of note, some parasitic infections, such as primary amebic meningoencephalitis, cannot be distinguished from acute bacterial meningoencephalitis by CSF profile alone and will require a history of freshwater exposure to further delineate.

Data from refs.^{45–53}

and *Cryptococcus* spp. had the highest proportions of false negatives when sending multiplex PCR panels.⁵⁷ In clinical practice, if multiplex panels return negative but the suspicion for certain bacterial, viral, and fungal meningitides and encephalitides persist, de-escalation of antimicrobials should occur only after dedicated PCR testing of the specific pathogen.

Head Imaging

Prior to an LP, head imaging should be pursued to rule out mass lesions or other causes of elevated ICP that could place a patient at risk for herniation. A computed tomographic (CT) scan is generally adequate for this screening.

The IDSA recommends pursuing head imaging if a patient meets any of the following:

- Immunocompromised state
- History of CNS disease
- New-onset seizure
- Papilledema
- Altered mental status
- New focal neurologic deficit.

Despite these guidelines, one observational study demonstrated over-utilization of head imaging, citing the use in 65% of patients who did not meet criteria.²

MRI may also be a helpful diagnostic tool. In patients with meningoencephalitis, almost 50% of patients will have MRI findings of abnormal meningeal enhancement on post-contrast T1 sequences and hyperintensity on fluid-attenuated inversion recovery (FLAIR) sequences.^{58,59} A common misconception is delaying an LP to obtain

Table 4
MRI findings in meningitis and encephalitis by pathogen

<i>Mycobacterium tuberculosis</i>	Leptomeningeal Enhancement, Hydrocephalus, Vasculitis, Tuberculomas
<i>Cryptococcus neoformans</i>	Leptomeningeal enhancement, Pseudocysts, Cryptococcomas
<i>Candida albicans</i> <i>A. fumigatus</i>	Abscesses, Vascular lesions
HSV-1	T2 and FLAIR hyperintensities in the medial temporal lobes, sometimes associated with hemorrhagic foci
VZV	Leptomeningeal enhancement, Cerebellitis
CMV	Periventricular white matter T2 FLAIR hyperintensities
WNV	T2 and FLAIR hyperintensities in basal ganglia, thalamus, midbrain
Enterovirus	Rhombencephalitis
<i>Listeria monocytogenes</i>	Subcortical abscesses, Cranial nerve enhancement
<i>Borrelia burgdorferi</i>	Single or multiple small non-enhancing subcortical or periventricular white matter hyperintensities, most often supratentorial
<i>Toxoplasma gondii</i>	Multiple concentric and eccentric enhancing lesions, primarily in the basal ganglia, thalami, cortico-medullary junction

Adapted from Perillo T, Capasso R, Pinto A. Neuroimaging of the Most Common Meningitis and Encephalitis of Adults: A Narrative Review. *Diagnostics* 2024;14(11):1064. <https://doi.org/10.3390/diagnostics14111064>; with permission.

Data from refs.^{41,59,61}




Fig. 1. Neuroradiology findings of meningitis and encephalitis caused by various pathogens. (A–B) T2 FLAIR hyperintensities of the L medial temporal lobe and the bilateral insula in HSV

an MRI so as to avoid iatrogenic meningeal enhancement. Studies have shown that *unexplained* meningeal enhancement after LP is very rare and not more common than in cases with no prior LP. If an LP is performed before MRI and meningeal enhancement is found, it should only be attributed to the LP after all other causes have been ruled out.⁶⁰ Key MRI findings of common pathogens, summarized by Perillo and colleagues, are highlighted in **Table 4** and **Fig. 1**.^{41,59,61}

Seizures are a common complication of encephalitis and, less frequently, meningitis.⁶² Clinical and electrographic seizures, the latter may be difficult to detect on bedside assessment, lead to worse outcomes both during hospitalization and long-term for affected patients.⁶³ In a retrospective cohort study by Carrera and colleagues on patients with CNS infection and persistent altered mental status, 33% of patients with CNS infection had electrographic seizures, most without any clinical correlate. Of note, 86% of these patients had evidence of a clinical seizure prior to EEG monitoring.⁶² The utilization of EEG monitoring is thus important for prevention of secondary neurologic injury. EEG monitoring should also be pursued in patients with prior evidence of a clinical seizure or persistently poor mental status.

DIFFERENTIAL DIAGNOSIS

Though meningitis and encephalitis have characteristic clinical features, such as nuchal rigidity, there are a variety of other conditions that can mimic the clinical features of meningitis and encephalitis. These are outlined in **Table 5** along with their associated workup.

DISCUSSION OF MANAGEMENT

The first step in managing CNS infections is ensuring a stable airway, breathing, and circulatory support (ABCs).

Antimicrobials

Once ABCs are addressed, prompt initiation of antimicrobials should ensue. Empirical antimicrobials should be tailored toward patient risk factors (**Table 1**). As previously mentioned, antibiotics should not be delayed for imaging or an LP. With delays, the morbidity and mortality in these patients increases. A retrospective case study of 123 cases of adult bacterial meningitis found an adjusted odds ratio of 8.4 for mortality in patients who received antibiotics over 6 hours after presentation.⁶⁴ Empirical antibiotics include vancomycin and ceftriaxone or cefotaxime.^{47,53} Ampicillin for *Listeria monocytogenes* coverage is recommended in immunocompromised adults or adults older than 50 years of age.⁶⁵ For empirical coverage of HSV encephalitis, acyclovir should be added.⁶⁶ **Table 6** lists additional common pathogens and their associated treatments based on IDSA guidelines.^{2,25,47,50,66,67}

encephalitis. (C–D) Multifocal luminal irregularity and stenosis of the right middle cerebral artery and its branches in a patient with CMV meningoencephalitis. (E–F) Left medial temporal lobe and insular enhancement in a patient with *Candida auris* meningitis. (G–H) Multifocal ring-enhancing lesions in the cerebellum and brainstem in a patient with *Listeria monocytogenes* meningitis. (I) Leptomeningeal enhancement in a patient with *Streptococcus pneumoniae* meningitis. (J) Pachymeningeal enhancement in the same patient with *S pneumoniae* meningitis. CMV, cytomegalovirus; HSV, Herpes Simplex virus.

Table 5 Differential Diagnoses and Workup	
Chemical and Drug Induced Meningitis	Medication Review for drugs Such as intravenous immunoglobulin, Non-Steroidal Anti-Inflammatory drugs, intrathecal Administration of Chemotherapy or Antibiotics
Autoimmune Meningitis	Subacute onset, associated movement and mood disorders. Serum and CSF autoimmune and paraneoplastic panels MRI brain demonstrating temporal lobe enhancement or T2 hyperintensity
Toxidromes	Medication and history review for alcohol and drug intoxication or withdrawal, serotonergic and anti-cholinergic medications, baclofen withdrawal
Subarachnoid Hemorrhage	Presents similarly with meningismus and headache Stat CT Head and CT Angiography to rule out aneurysmal rupture Lumbar puncture for xanthochromia
Posterior Reversible Encephalopathy Syndrome	MRI Brain demonstrating bilateral T2 Hyperintense lesions EEG to rule out concurrent seizures
Reversible Cerebral Vasoconstriction Syndrome	CT angiography for MR angiography for assessment of vessel abnormalities Digital Subtraction Angiography as the gold standard Medication review of culprit medications
Cerebral Venous Sinus Thrombosis	CT or MR venogram

Corticosteroids

Given the association of bacterial lysis and inflammation in the subarachnoid space with poor outcome, adjuvant treatment with corticosteroids has been added to meningitis regimens to reduce this inflammation and neurological sequelae from meningitis. In a prospective, randomized multicenter trial, dexamethasone 10 mg every 6 hours was compared with placebo in adults with bacterial meningitis. Results demonstrated a significantly lower rate of unfavorable outcomes in the dexamethasone group.⁶⁸ IDSA guidelines recommend the use of dexamethasone in adults with suspected or proven pneumococcal meningitis, ideally before or with the first dose of antibiotics.⁴⁷

Elevated Intracranial Pressure and Hydrocephalus

Patients with bacterial, fungal, and rarely, viral meningitis may develop hydrocephalus and elevated intracranial pressure (ICP). This is due to the loss of cerebrovascular autoregulation with increased vasodilation, venous thrombophlebitis producing venous congestion, and the development of hydrocephalus due to impaired CSF flow and reabsorption.⁶⁹ Hydrocephalus will be evident on head imaging, while an LP can identify patients with elevated ICP. Elevated ICP in adults is defined as a measurement above 20 mm Hg. Additionally, physical examination findings include a worsening mental status, pupillary changes or papilledema, posturing, or decreased Glasgow Coma Scale (GCS) score. If not addressed, these patients will be at risk for increased morbidity and mortality. At present, there is no consensus on whether to monitor ICP or how to manage ICP elevation in these patients.⁶⁹ Frequent

Table 6
Antimicrobial treatment of meningitis and encephalitis based on common pathogens

<i>Bacterial</i>	
<i>Streptococcus pneumoniae</i>	Vancomycin and ceftriaxone or cefotaxime
<i>Neisseria meningitidis</i>	Ceftriaxone or cefotaxime
<i>Listeria monocytogenes</i> <i>Streptococcus agalactiae</i>	Ampicillin or penicillin G (may also consider addition of gentamicin)
<i>Hemophilus influenzae</i>	Ceftriaxone or cefotaxime
<i>Escherichia coli</i>	Ceftriaxone or cefotaxime
<i>Mycoplasma pneumoniae</i>	Azithromycin, doxycycline, or a fluoroquinolone may be considered
<i>Mycobacterium tuberculosis</i>	Isoniazid, rifampin, pyrazinamide, ethambutol x 2 mo Isoniazid and rifampin for additional 10 mo
<i>Borrelia burgdorferi</i>	Ceftriaxone, cefotaxime or penicillin G
<i>Treponema pallidum</i>	Penicillin G
<i>Viral</i>	
HSV-1, 2	Acyclovir
VZV	Acyclovir or ganciclovir
CMV	Ganciclovir and foscarnet
EBV	Supportive, may consider steroids if benefits outweigh risks
<i>Fungal and Protozoa</i>	
<i>Coccidioides spp</i>	Fluconazole Alternatives include itraconazole, voriconazole and amphotericin B
<i>Cryptococcus neoformans</i>	Amphotericin B and flucytosine
<i>Histoplasma capsulatum</i>	Amphotericin B followed by itraconazole
<i>Acanthamoeba</i>	Trimethoprim-sulfamethoxazole plus rifampin plus ketoconazole can be considered
<i>Naegleria fowleri</i>	Amphotericin B and rifampin can be considered
<i>Toxoplasma gondii</i>	Pyrimethamine plus either sulfadiazine or clindamycin is recommended

Data from^{2,25,47,50,66,67}

neurologic examinations, a high clinical index of suspicion, and multidisciplinary involvement of Neurocritical Care, Neurosurgery, and Infectious Diseases (ID) teams is crucial.

In any patient with elevated ICP, a stepwise approach for management may be followed. At minimum, this includes elevating the head of bed (HOB) to at least 30° and ensuring adequate sedation, analgesia, fever control, hyperosmolar therapy and discussions regarding surgical CSF diversion or decompression. Higher blood pressures may be observed during this time to maintain cerebral perfusion pressure. If blood pressure medications are required for severe hypertension, intravenous (IV) or short acting medications should be utilized. If a patient is mechanically ventilated, a brief period of hyperventilation for goal (partial pressure of arterial

Table 7 Management of Elevated Intracranial Pressure	
Supportive Measures	HOB > 30° Head midline Brief course (<2 h) of hyperventilation for end-tidal CO ₂ goal 30–35 Sedation and analgesia Fever and pain control Seizure control
Hyperosmolar Therapy	Hypertonic saline (HTS) • 5 cc/kg bolus of 3% over 5–20 min • 3 cc/kg bolus of 5% over 5–20 min • 2 cc/kg bolus of 7.5% over 10–20 min • 30 cc of 23.4% over 5–10 min with close hemodynamic monitoring if acute herniation • Hold for sodium > 160 meq/L • Concentrations higher than 3% should be administered via central line or intraosseous line Mannitol 20% • Dose: 0.5–1 g/kg IV bolus up to 100g over 5–15 min • Place foley, given rapid diuresis, and administer additional isotonic intravenous fluids to prevent intravascular volume depletion • Avoid in end-stage renal disease and anuric patients • Hold for serum osmolality > 320 or osmolar gap > 20 mOsm/kg • Can be repeated every 4–6 h
Additional ICP Measures	CSF diversion Hypothermia or Targeted Temperature Management Pentobarbital Paralysis

Data adapted from Ref.⁷¹

carbon dioxide) PaCO₂ 30 to 35 mm Hg is appropriate. If there is a concern for seizures, anti-seizure medications (ASMs) should be administered promptly.

Once all core measures are addressed, hyperosmolar therapy should be administered without delay guided by ICP or worsening physical examination findings, such as obtundation, pupillary changes, or posturing. Of note, Neurocritical Care Society (NCS) guidelines highlight the scarcity of literature addressing the use of hyperosmolar therapy for elevated ICP in the setting of meningitis. However, the panel recognized one study that demonstrated improved mortality with ICP control.⁷⁰ **Table 7** summarizes various types of hyperosmolar therapy recommended by NCS in the general management of intracranial hypertension.⁷¹ In cases of acute herniation, 30 cc of 23.4% hypertonic saline should be administered promptly via either a central venous catheter or an intraosseous catheter. Other interventions in the step-wise ICP ladder include hypothermia or targeted temperature management, barbiturate therapy, paralysis, and surgical intervention, such as decompressive craniotomy, which could be utilized in cases of refractory ICP in meningitis.⁷²

Presently, there is no algorithmic approach for when to pursue CSF diversion and surgical management. A systematic review of management strategies for raised ICP in meningitis and encephalitis included external ventricular devices, lumbar drains (LD), ventriculoperitoneal shunts, intraparenchymal monitors, and decompressive craniotomy. Despite variable approaches for detecting and managing elevated ICP, this review demonstrated that, in the adult population, CSF drainage, in addition to conventional therapy, reduced both morbidity and mortality.⁶⁹ Another study

highlighted similar findings and additionally found that it was rare to require barbiturate coma or decompressive craniotomies once patients were treated with CSF drainage.⁷³ A study utilizing LD in patients with acute bacterial meningitis found that LD drainage, when set at a maximum drainage of 10 cc/hr and ICP of 10 mm Hg, was associated with 0% mortality compared with 15% in the non-LD group.⁷⁴ In resource-limited settings, serial LPs, have been demonstrated to improve survival at least in patients with *Cryptococcus* meningitis, may be the only option for ICP monitoring and CSF drainage.⁷⁵

Seizures

As previously mentioned, EEG monitoring is helpful in identifying electrographic seizures. Empirical initiation of ASMs is usually not necessary. If patients are in status epilepticus, either convulsive or non-convulsive, a stepwise escalation of ASMs based on American Epilepsy Society and NCS guidelines is recommended.

Hyponatremia

Another cause of morbidity and mortality in meningitis and encephalitis is hyponatremia, which may be caused by cerebral salt wasting, diabetes insipidus, and Syndrome of Inappropriate Anti-diuretic Hormone. Prompt recognition and management are crucial as hyponatremia, as well as its correction, may cause cerebral swelling, further adverse outcomes, and increased mortality for patients.⁷⁶ If severe, hyponatremia may cause further alterations in mental status, seizures, and—without treatment or inappropriately rapid correction—at worst, coma or death. For these patients, a pragmatic approach focusing on the etiology of hyponatremia will help with treatment. Close attention should be paid to the rate of correction to prevent secondary neurologic injury.

Vascular complications

Vascular complications could be seen in bacterial, fungal, tubercular meningitis. This could include septic cerebral sinus venous thrombosis, septic cortical vein thrombosis, vasculitis, cerebral ischemia, subarachnoid hemorrhage, and intracerebral hemorrhage. These complications vary in incidence depending upon the underlying organism and patient specific risk factors. For example, vasculitis maybe seen in up to 30% streptococcal meningitis patients and is associated with a high risk of morbidity and mortality.⁷⁷

From their time of arrival to their discharge, patients with meningitis and encephalitis require multi-disciplinary team involvement, including Internal Medicine, ID, Neurology, Critical Care, Neurocritical Care, and Neurosurgery if there are any concerns for raised ICP. Disposition could be variable and may include a general floor, step-down unit, or an intensive care unit. However, the clinical course remains dynamic and escalation of monitoring can occur at any time.

PROGNOSIS

Prognosis of meningitis and encephalitis varies between the two and among pathogens as well. As previously mentioned, mortality rates in meningitis vary from 10% in high-income countries to 58% in low-income countries; in encephalitis, mortality rates are up to 39.3%, with nearly 50% of survivors suffering profound neurological deficits, including hearing loss, seizure disorders, and cognitive impairments.^{2–4} Even with treatment in some cases and with certain pathogens, mortality and morbidity may remain high. For example, the mortality in HSV encephalitis with and without treatment has been documented as 19% and 70%, respectively.⁷⁸ Additionally, one case series showed that 30% to 70% of survivors have significant neurologic sequela.⁷⁸ Similarly,

in cases of treated tuberculous meningitis, short-term in-hospital mortality rates are up to 50% and increase to 58% for long-term 5 year mortality, with post-treatment disability varying between 29% and 50%.^{79–81} The goal in these patients is to treat the primary neurologic disorder while preventing secondary neurologic injury. Post-ICU care of the patient should focus on ongoing monitoring of their neurologic status, gradual weaning of supportive therapies, and initiation of supportive rehabilitation to address any residual cognitive, sensory, coordinative, or motor deficits. These will include physical, occupation, and speech therapy, cognitive rehabilitation, audiology support, continued follow-up with epileptologists, and psychosocial support. Once medically stable for discharge, patients and families should be counseled about medication administration and adherence and symptom monitoring and management. In addition, they should be connected to an outpatient specialist for continued evaluation and care in the outpatient setting.

SUMMARY

Meningitis and encephalitis are conditions frequently associated with significant morbidity and mortality. Caused by a variety of pathogens, recognition and rapid initiation of treatment is crucial in decreasing neurological injury and preventing death. These interventions include antibiotics, steroids, targeted therapies toward reducing ICP, and, in severe cases, neurosurgical intervention. With timely recognition, intervention, multidisciplinary team coordination, and structured follow-up, hospitalized patients with meningitis and encephalitis can achieve meaningful neurologic recovery.

CLINICS CARE POINTS

- CSF studies are crucial to the diagnosis of meningitis. If an LP is done in the early acute phase of meningitis or encephalitis, it may yield negative results. If the suspicion of meningitis or encephalitis remains high, a repeat LP should be performed, and antibiotics should be continued.
- Head imaging prior to an LP is only recommended in certain patient populations. However, from a diagnostic perspective, it may provide additional information about the pathogen.
- Initiation of antibiotics should not be delayed by an LP. In acute bacterial meningitis, IDSA guidelines recommend administration of steroids alongside the first dose of antibiotics.
- In patients with a worsening mental status, pupillary changes or papilledema, posturing, or decreased GCS, empirical treatment of elevated ICP should be initiated promptly. This should be pursued in a stepwise fashion.
- CSF diversion, as well as therapeutic LPs, may reduce mortality in patients with hydrocephalus and elevated ICP.
- Early involvement of Infectious Disease, Critical Care, Neurocritical Care, Neurology, and Neurosurgery teams is important for high-quality multidisciplinary management of critically ill patients with meningitis and encephalitis.

DISCLOSURE

The authors have no financial disclosures or conflicts of interest to disclose.

REFERENCES

1. Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. *JAMA* 2009;302(21):2323.

2. Hasbun R. Progress and challenges in bacterial meningitis. *JAMA* 2022;328(21):2147.
3. Wang F, Wang Y, He J, et al. Clinical characteristics and risk factors for mortality in cryptococcal meningitis: evidence from a cohort study. *Front Neurol* 2022;13. <https://doi.org/10.3389/fneur.2022.779435>.
4. van de Beek D, de Gans J, Spanjaard L, et al. Clinical features and prognostic factors in adults with bacterial meningitis. *N Engl J Med* 2004;351(18):1849–59.
5. Makkawi S, Alqurashi S, Hubayni W, et al. The clinical manifestations, risk factors, etiologies, and outcomes of adult patients with infectious meningitis and encephalitis: single center experience. *Neurol Int* 2024;16(5):966–75.
6. Mailles A, Stahl J, Steering Committee and Investigators Group. Infectious encephalitis in France in 2007: a National Prospective Study. *Clin Infect Dis* 2009;49(12):1838–47.
7. Doran KS, Fulde M, Gratz N, et al. Host–pathogen interactions in bacterial meningitis. *Acta Neuropathol* 2016;131(2):185–209.
8. Duerlund LS, Nielsen H, Bodilsen J. Current epidemiology of infectious encephalitis: a narrative review. *Clin Microbiol Infection* 2025;31(4):515–21.
9. Tyler KL. Acute viral encephalitis. *N Engl J Med* 2018;379(6):557–66.
10. Basaran S, Yavuz SS, Bali EA, et al. Hyponatremia is predictive of HSV-1 encephalitis among patients with viral encephalitis. *Tohoku J Exp Med* 2019;247(3):189–95.
11. Khalilzadegan A, Hadianfard AM, Ekrami A, et al. Characteristics and distribution of fungal meningitis: a systematic review. *Infectious Diseases and Clinical Microbiology* 2025;7(2):114–22.
12. Qureshi ZA, Ghazanfar H, Altaf F, et al. Cryptococcosis and cryptococcal meningitis: a narrative review and the up-to-date management approach. *Cureus* 2024;16(3):e55498.
13. Arshad A, Dayal S, Gadhe R, et al. Analysis of tuberculosis meningitis pathogenesis, diagnosis, and treatment. *J Clin Med* 2020;9(9):2962.
14. Litvinjenko S, Magwood O, Wu S, et al. Burden of tuberculosis among vulnerable populations worldwide: an overview of systematic reviews. *Lancet Infect Dis* 2023;23(12):1395–407.
15. Huynh J, Donovan J, Phu NH, et al. Tuberculous meningitis: progress and remaining questions. *Lancet Neurol* 2022;21(5):450–64.
16. Thwaites GE, van Toorn R, Schoeman J. Tuberculous meningitis: more questions, still too few answers. *Lancet Neurol* 2013;12(10):999–1010.
17. Lourens R, Singh G, Arendse T, et al. Tuberculous meningitis across the lifespan. *Journal of Infectious Diseases*. Oxford University Press 2025;231(5):1101–11.
18. Huang M, Ma Y, Ji X, et al. A study of risk factors for tuberculous meningitis among patients with tuberculosis in China: an analysis of data between 2012 and 2019. *Front Public Health* 2023;10. <https://doi.org/10.3389/fpubh.2022.1040071>.
19. Leonard JM. Central nervous system tuberculosis. *Microbiol Spectr* 2017;5(2). <https://doi.org/10.1128/microbiolspec.TNMI7-0044-2017>.
20. Mezocho A, Thakur K, Vinnard C. Tuberculous meningitis in children and adults: new insights for an ancient foe. *Curr Neurol Neurosci Rep* 2017;17(11):85.
21. Dubey H, Oster P, Fazeli MS, et al. Risk factors for contracting invasive meningococcal disease and related mortality: a systematic literature review and meta-analysis. *Int J Infect Dis* 2022;119:1–9.
22. Lécuyer H, Borgel D, Nassif X, et al. Pathogenesis of meningococcal purpura fulminans. *Pathog Dis* 2017;75(3). <https://doi.org/10.1093/femspd/ftx027>.

23. Ferguson LE, Hormann MD, Parks DK, et al. *Neisseria meningitidis*: presentation, treatment, and prevention. *J Pediatr Health Care* 2002;16(3):119–24.
24. Hoogman M, van de Beek D, Weisfelt M, et al. Cognitive outcome in adults after bacterial meningitis. *J Neurol Neurosurg Psychiatry* 2007;78(10):1092–6.
25. Brouwer MC, Tunkel AR, van de Beek D. Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis. *Clin Microbiol Rev* 2010;23(3):467–92.
26. Kruckow KL, Zhao K, Bowdish DME, et al. Acute organ injury and long-term sequelae of severe pneumococcal infections. *Pneumonia* 2023;15(1):5.
27. Gil E, Wall E, Noursadeghi M, et al. *Streptococcus pneumoniae* meningitis and the CNS barriers. *Front Cell Infect Microbiol* 2022;12:1106596.
28. Schlech WF. Epidemiology and clinical manifestations of *Listeria monocytogenes* infection. *Microbiol Spectr* 2019;7(3). <https://doi.org/10.1128/microbiolspec.GPP3-0014-2018>.
29. Koopmans MM, Brouwer MC, Vázquez-Boland JA, et al. Human listeriosis. *Clin Microbiol Rev* 2023;36(1):e0006019.
30. Armstrong RW, Fung PC. Brainstem encephalitis (Rhombencephalitis) due to *listeria monocytogenes*: case report and review. *Clin Infect Dis* 1993;16(5):689–702.
31. Tyrberg T, Hagberg L, Nilsson S, et al. Incidence and risk factors for varicella-zoster virus-associated central nervous system infections: a nationwide Swedish retrospective case-control study. *J Med Virol* 2025;97(2):e70166.
32. Herlin LK, Hansen KS, Bodilsen J, et al. Varicella zoster virus encephalitis in Denmark from 2015 to 2019—A nationwide prospective cohort study. *Clin Infect Dis* 2021;72(7):1192–9.
33. Charalambous LT, Premji A, Tybout C, et al. Prevalence, healthcare resource utilization and overall burden of fungal meningitis in the United States. *J Med Microbiol* 2018;67(2):215–27.
34. Cárdenas G, Aristizábal S, Salinas C, et al. Coccidioidal meningitis in non-AIDS patients. A case series at a Mexican neurological referral center. *Clin Neurol Neurosurg* 2020;196:106011.
35. Nguyen MH, Yu VL. Meningitis caused by *Candida* species: an emerging problem in neurosurgical patients. *Clin Infect Dis* 1995;21(2):323–7.
36. Chen M, Chen C, Yang Q, et al. *Candida* meningitis in neurosurgical patients: a single-institute study of nine cases over 7 years. *Epidemiol Infect* 2020;148:e148.
37. Fernandez M, Moylett EH, Noyola DE, et al. Candidal meningitis in neonates: a 10-Year review. *Clin Infect Dis* 2000;31(2):458–63.
38. Brehm TJ, Staggers KA, Hamill RJ, et al. Central nervous system histoplasmosis: a retrospective review of clinical characteristics, treatments and outcomes with comparison to disseminated histoplasmosis without central nervous system involvement. *Mycoses* 2025;68(5). <https://doi.org/10.1111/myc.70068>.
39. Ahmad Zamzuri M, Ammar I, Abd Majid FN, et al. Systematic review of brain-eating amoeba: a decade update. *Int J Environ Res Publ Health* 2023;20(4):3021.
40. Berger JR. Amebic infections of the central nervous system. *J Neurovirol* 2022;28(4–6):467–72.
41. Elsheikha HM, Marra CM, Zhu XQ. Epidemiology, pathophysiology, diagnosis, and management of cerebral toxoplasmosis. *Clin Microbiol Rev* 2020;34(1). <https://doi.org/10.1128/CMR.00115-19>.
42. Thebault A, Kooh P, Cadavez V, et al. Risk factors for sporadic toxoplasmosis: a systematic review and meta-analysis. *Microb Risk Anal* 2021;17:100133.
43. Graham AK, Fong C, Naqvi A, et al. Toxoplasmosis of the central nervous system: manifestations vary with immune responses. *J Neurol Sci* 2021;420:117223.

- 44.. Qasim A, Abraham MC, Javed N, et al. Unveiling the truth: diagnosing bacterial meningitis through repeat lumbar punctures. *Cureus* 2022;15(6):e40811.
45. Shahan B, Choi EY, Nieves G. Cerebrospinal fluid analysis. *Am Fam Physician* 2021;103(7):422–8.
46. Reiber H, Peter JB. Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs. *J Neurol Sci* 2001;184(2):101–22.
47. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. *Clin Infect Dis* 2004;39(9):1267–84.
48. Straus SE, Thorpe KE, Holroyd-Leduc J. How do I perform a lumbar puncture and analyze the results to diagnose bacterial meningitis? *JAMA* 2006;296(16):2012.
49. Marais S, Thwaites G, Schoeman JF, et al. Tuberculous meningitis: a uniform case definition for use in clinical research. *Lancet Infect Dis* 2010;10(11):803–12.
50. van de Beek D, de Gans J, Tunkel AR, et al. Community-acquired bacterial meningitis in adults. *N Engl J Med* 2006;354(1):44–53.
51. Whiteley W, Al-Shahi R, Warlow CP, et al. CSF opening pressure: reference interval and the effect of body mass index. *Neurology* 2006;67(9):1690–1.
52. Gompf SG, Garcia C. Lethal encounters: the evolving spectrum of amoebic meningoencephalitis. *IDCases* 2019;15:e00524.
53. Carter E, McGill F. The management of acute meningitis: an update. *Clin Med* 2022;22(5):396–400.
54. de Montmollin E, Dupuis C, Jaquet P, et al. Herpes simplex virus encephalitis with initial negative polymerase chain reaction in the cerebrospinal fluid: prevalence, associated factors, and clinical impact. *Crit Care Med* 2022;50(7):e643–8.
- 55.. Miller JM, Binnicker MJ, Campbell S, et al. Guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2024 update by the infectious diseases society of America (IDSA) and the American society for microbiology (ASM). *Clin Infect Dis* 2024;ciae104. <https://doi.org/10.1093/cid/ciae104>.
56. Trujillo-G Omez J, Tsokani S, Arango-Ferreira C, et al. Biofire FilmArray meningitis/encephalitis panel for the aetiological diagnosis of central nervous system infections: a systematic review and diagnostic test accuracy meta-analysis. *eClinical-Medicine* 2022;44:101275.
57. Tansarli GS, Chapin KC. Diagnostic test accuracy of the BioFire® FilmArray® meningitis/encephalitis panel: a systematic review and meta-analysis. *Clin Microbiol Infection* 2020;26(3):281–90.
58. Abbuehl LS, Branca M, Ungureanu A, et al. Magnetic resonance imaging in acute meningoencephalitis of viral and unknown origin: frequent findings and prognostic potential. *Front Neurol* 2024;15. <https://doi.org/10.3389/fneur.2024.1359437>.
59. Perillo T, Capasso R, Pinto A. Neuroimaging of the Most common meningitis and encephalitis of adults: a narrative review. *Diagnostics* 2024;14(11):1064.
60. Wesley SF, Garcia-Santibanez R, Liang J, et al. Incidence of meningeal enhancement on brain MRI secondary to lumbar puncture. *Neurol Clin Pract* 2016;6(4):315–20.
61. Zawadzki R, Rogalska W, Pałdyna M, et al. Imaging modalities in neurolisterosis: a literature review. *Pol J Radiol* 2024;89:345–57.
62. Carrera E, Claassen J, Oddo M, et al. Continuous electroencephalographic monitoring in critically ill patients with central nervous system infections. *Arch Neurol* 2008;65(12). <https://doi.org/10.1001/archneur.65.12.1612>.
63. Wang KW, Chang WN, Chang HW, et al. The significance of seizures and other predictive factors during the acute illness for the long-term outcome after bacterial meningitis. *Seizure* 2005;14(8):586–92.

64. Proulx N, Fréchette D, Toye B, et al. Delays in the administration of antibiotics are associated with mortality from adult acute bacterial meningitis. *QJM* 2005;98(4): 291–8.
65. Young N, Thomas M. Meningitis in adults: diagnosis and management. *Intern Med J* 2018;48(11):1294–307.
66. Tunkel AR, Glaser CA, Bloch KC, et al. The management of encephalitis: clinical practice guidelines by the infectious diseases society of America. *Clin Infect Dis* 2008;47(3):303–27.
67. Nahid P, Dorman SE, Alipanah N, et al. Official American thoracic Society/Centers for disease control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. *Clin Infect Dis* 2016;63(7):e147–95.
68. de Gans J, van de Beek D, European Dexamethasone in Adulthood Bacterial Meningitis Study Investigators. Dexamethasone in adults with bacterial meningitis. *N Engl J Med* 2002;347(20):1549–56.
69. El-Hajj VG, Pettersson I, Gharos M, et al. Detection and management of elevated intracranial pressure in the treatment of acute community-acquired bacterial meningitis: a systematic review. *Neurocritical Care* 2024;41(1):228–43.
70. Cook AM, Morgan Jones G, Hawryluk GWJ, et al. Guidelines for the acute treatment of cerebral edema in neurocritical care patients. *Neurocritical Care* 2020; 32(3):647–66.
71. Brophy GM, Human T. Pharmacotherapy pearls for emergency neurological life support. *Neurocritical Care* 2017;27(S1):51–73.
72. EDBERG M, FUREBRING M, SJÖLIN J, et al. Neurointensive care of patients with severe community-acquired meningitis. *Acta Anaesthesiol Scand* 2011;55(6): 732–9.
73. Svedung Wettervik T, Howells T, Ljunghill Hedberg A, et al. Intracranial pressure dynamics and cerebral vasomotor reactivity in community-acquired bacterial meningitis during neurointensive care. *J Neurosurg* 2022;136(3):831–9.
74. Abulhasan YB, Al-Jehani H, Valiquette MA, et al. Lumbar drainage for the treatment of severe bacterial meningitis. *Neurocritical Care* 2013;19(2):199–205.
75. Jjunju S, Nuwagira E, Meya DB, et al. Persistently elevated intracranial pressure in cryptococcal meningitis– 76 therapeutic lumbar punctures. *Med Mycol Case Rep* 2023;40:50–3.
76. Lim AKH, Paramaswaran S, Jellie LJ, et al. A cross-sectional study of hyponatremia associated with acute central nervous system infections. *J Clin Med* 2019;8-(11):1801.
77. Deliran SS, Brouwer MC, van de Beek D. Cerebrovascular complications in bacterial meningitis. *Stroke: Vascular and Interventional Neurology* 2025;5(1):e001435.
78. Whitley RJ. Herpes simplex encephalitis: adolescents and adults. *Antivir Res* 2006;71(2–3 SPEC. ISS.):141–8.
79. Kvam KA, Stahl JP, Chow FC, et al. Outcome and sequelae of infectious encephalitis. *Journal of Clinical Neurology (Korea). Korean Neurological Association* 2024; 20(1):23–36.
80. Evans EE, Avaliani T, Gujabidze M, et al. Long term outcomes of patients with tuberculous meningitis: the impact of drug resistance. *PLoS One* 2022;17(6 June). <https://doi.org/10.1371/journal.pone.0270201>.
81. Stadelman AM, Ellis J, Samuels THA, et al. Treatment outcomes in adult tuberculous meningitis: a systematic review and meta-analysis. *Open Forum Infect Dis.- Oxford University Press* 2020;7(8). <https://doi.org/10.1093/ofid/ofaa257>.